IP Library › Granted Patent US 7,119,117
Granted Patent B2
US 7,119,117 · App. 10/227,094 · Granted Oct 10, 2006

Tocopherol enriched compositions and amelioration of inflammatory symptoms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,119,117
App. No.
10/227,094
Granted
Oct 10, 2006
Kind
B2
Abstract

The present invention provides non-alpha-tocopherol enriched tocopherol compositions and non-alpha-tocopherol metabolite enriched compositions for use in the reduction of inflammatory markers associated with inflammation such as C-reactive protein.

Claims (17)

1. A method of reducing the level of C-reactive protein (CRP) in an individual subject to a CRP associated inflammatory condition comprising administering to the individual an effective amount of a non-alpha-tocopherol enriched tocopherol composition, wherein said non-alpha tocopherol is selected from the group consisting of gamma-toconherol, beta-tocopherol and delta tocopherol, and wherein said composition comprises less than 30% alpha-toconherol.

2. The method of claim 1 wherein said non-alpha-tocopherol is gamma tocopherol.

3. The method of claim 1 wherein said non-alpha-tocopherol is beta-tocopherol.

4. The method of claim 1 wherein said non-alpha-tocopherol is delta-tocopherol.

5. The method of claim 1 , wherein said composition comprises less than 25% alpha-tocopherol.

6. The method of claim 5 , wherein said composition comprises less than 20% alpha-tocopherol.

7. The method of claim 6 , wherein said composition comprises less than 15% alpha-tocopherol.

8. The method of claim 7 , wherein said composition comprises less than 10% alpha-tocopherol.

9. The method of claim 8 , wherein said composition comprises less than 5% alpha-tocopherol.

10. A method of reducing the level of C-reactive protein (CRP) in an individual subject to a CRP associated inflammatory condition comprising administering to the individual an effective amount of non-alpha-tocopherol enriched tocopherol composition, wherein said composition comprises at least 60% ganima-tocopherol, at least 28% delta-tocopherol and no greater than 10% alpha-tocopherol.

11. A method of reducing the level of C-reactive protein (CRP) in an individual subject to a CRP associated inflammatory condition comprising administering to the individual an effective amount of a metabolite of a non-alpha-tocopherol selected from the group consisting of a beta-tocopherol metabolite, a gamma-tocopherol metabolite and a delta-tocopherol metabolite.

12. The method of claim 11 wherein said non-alpha-tocopherol metabolite is a gamma-tocopherol metabolite.

13. The method of claim 12 wherein said gamma-tocopherol metabolite is 2,7,8-trimethyl-2-(2′-carboxyethyl)-6-hydroxychroman (gamma-CEHC).

14. The method of claim 11 wherein said non-alpha-tocopherol is a beta-tocopherol metabolite.

15. The method of claim 14 wherein said beta-tocopherol metabolite is 2,5,8-trimethyl-2-(2-carboxyethyl)-6-hydroxychroman (beta-CEHC).

16. The method of claim 11 wherein said non-alpha-tocopherol is a delta-tocopherol metabolite.

17. The method of claim 16 wherein said delta-tocopherol metabolite is 2,8-dimethyl-2-(2-carboxyethyl)-6-hydroxychroman (delta-CEHC).

Assignments (14)
CERTIFICATE OF CONVERSION Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0521 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2023
From: JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 062438/0372 →
MERGER Recorded Jan 27, 2022
From: JOHNSON & JOHNSON CONSUMER INC.
To: CHENANGO ZERO LLC
Reel/Frame 059618/0521 →
MERGER AND CHANGE OF NAME Recorded Jan 27, 2022
From: CHENANGO TWO LLC; CURRAHEE HOLDING COMPANY INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 058888/0210 →
MERGER Recorded Jan 27, 2022
From: CHENANGO ZERO LLC
To: CHENANGO TWO LLC
Reel/Frame 058888/0133 →
CORRECTIVE ASSIGNMENT TO CORRECT THE MERGED ENTITY' NEW NAME PREVIOUSLY RECORDED AT REEL: 036041 FRAME: 0605. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER & CHANGE OF NAME. Recorded Jul 21, 2015
From: JOHNSON & JOHNSON CONSUMER COMPANIES, LLC
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 036143/0449 →
MERGER Recorded Jul 1, 2015
From: JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
To: JOHNSON & JOHNSON CONSUMER COMPANIES, LLC
Reel/Frame 036043/0978 →
MERGER AND CHANGE OF NAME Recorded Jul 1, 2015
From: JOHNSON & JOHNSON CONSUMER COMPANIES, LLC; JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC
Reel/Frame 036041/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2006
From: GALILEO PHARMACEUTICALS, INC.
To: JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
Reel/Frame 018407/0725 →
RELEASE OF SECURITY INTEREST Recorded Sep 29, 2006
From: ALLOY VENTURES, INC., AS SECURED PARTY AND AS COLLATERAL AGENT FOR ADDITIONAL SECURED PARTIES UNDER THE SECURED NOTE PURCHASE AGREEMENT DATED AS OF DECEMBER 22, 2005
To: GALILEO PHARMACEUTICALS, INC.
Reel/Frame 018323/0228 →
SECURITY AGREEMENT Recorded Dec 22, 2005
From: GALILEO PHARMACEUTICALS, INC.
To: ALLOY VENTURES, INC.
Reel/Frame 016936/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2003
From: BEINLICH, PEGGY; BODDUPALL, SEKHAR; BROWN, LESLEY; FLAIM, STEPHEN; MILLER, GUY; DREON, DARLENE; PHINNEY, STEPHEN DODGE
To: GALILEO PHARMACEUTICALS, INC.
Reel/Frame 014071/0358 →
CHANGE OF NAME Recorded Jul 15, 2003
From: GALILEO LABORTORIES, INC.
To: GALILEO PHARMACEUTICALS, INC.
Reel/Frame 013805/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2002
From: BEINLICH, PEGGY; BODDUPALLI, SEKHAR; BROWN, LESLY A.; DREON, DARLENE M.; FLAIM, STEPHEN; MILLER, GUY; PHINNEY, STEPHEN D.
To: GALILEO LABORATORIES INC.
Reel/Frame 013550/0746 →